Fresenius Medical Care AG &Co KG (NYSE: FMS) has reported earnings for its second fiscal quarter (ending June 30) of $0.34 versus $0.27 for the same period a year ago. E.P.S. were $0.98 for the latest four quarters through June 30 versus $1.12 for the same period a year ago.
Recent Price Action
Fresenius Medical Care AG &Co KG (NYSE: FMS) stock declined by -3.6% on 7/30/24. The shares closed at $19.63. Moreover, exceptionally high trading volume at 234% of normal accompanied the decline. The stock has performed in line with the market over the last nine months and is unchanged during the last week.
Current PriceTarget Research Rating
FMS’ future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be an important Value Builder.
Fresenius Medical Care AG &Co KG has a current Value Trend Rating of B (Positive). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Fresenius Medical Care AG &Co KG has a very high Appreciation Score of 86 but a slightly negative Power Rating of 38, triggering the Positive Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment